Depramine

Last updated
Depramine
Depramine.png
Depramine-3D-balls.png
Clinical data
ATC code
  • None
Identifiers
  • 3-(5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C19H22N2
Molar mass 278.399 g·mol−1
3D model (JSmol)
  • c3cc2c(\C=C/c1c(cccc1)N2CCCN(C)C)cc3

Depramine (INN; GP-31,406), also known as balipramine (BAN) and as 10,11-dehydroimipramine, is a tricyclic antidepressant (TCA) which was never marketed. [1] [2]

See also

Related Research Articles

Melitracen

Melitracen is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol.

Dimetacrine

Dimetacrine, also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) used in Europe and formerly in Japan for the treatment of depression. It has imipramine-like effects; though, in a double-blind clinical trial against imipramine, dimetacrine was found to have lower efficacy in comparison and produced more weight loss and abnormal liver tests. Little is known about the pharmacology of dimetacrine, but it can be inferred that it acts in a similar manner to other TCAs. If this is indeed the case, dimetacrine may induce severe cardiac toxicity in overdose.

Demexiptiline

Demexiptiline is a tricyclic antidepressant (TCA) used in France for the treatment of depression. It acts primarily as a norepinephrine reuptake inhibitor similarly to desipramine.

Metapramine

Metapramine is a tricyclic antidepressant (TCA) developed by Rhone Poulenc that was introduced for the treatment of depression in France in 1984. In addition to its efficacy against affective disorders, it also has analgesic properties, and may be useful in the treatment of pain.

Noxiptiline

Noxiptiline, also known as noxiptyline and dibenzoxine, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1970s for the treatment of depression. It has imipramine-like effects, acting as a serotonin and norepinephrine reuptake inhibitor, among other properties. Of the TCAs, noxiptiline has been described as one of the most effective, rivaling amitriptyline in clinical efficacy.

Propizepine

Propizepine is a tricyclic antidepressant (TCA) used in France for the treatment of depression which was introduced in the 1970s.

Ketipramine

Ketipramine (G-35,259), also known as ketimipramine or ketoimipramine, is a tricyclic antidepressant (TCA) that was tested in clinical trials for the treatment of depression in the 1960s but was never marketed. It differs from imipramine in terms of chemical structure only by the addition of a ketone group, to the azepine ring, and is approximately equivalent in effectiveness as an antidepressant in comparison.

Fluotracen

Fluotracen (SKF-28,175) is a tricyclic drug which possesses dual antidepressant and antipsychotic activity. This profile of effects is similar to that of related agents like amoxapine, loxapine, and trimipramine which may also be used in the treatment of both depression and psychosis. It was believed that such duality would be advantageous in the treatment of schizophrenia, as depression is often comorbid with the disorder and usual antipsychotics often worsen such symptoms. In any case, however, fluotracen was never marketed.

Litracen

Litracen (N-7,049) is a tricyclic antidepressant which was never marketed.

Cotriptyline

Cotriptyline (SD-2203-01) is a tricyclic antidepressant (TCA) which was never marketed.

Tienopramine

Tienopramine is a tricyclic antidepressant (TCA) which was never marketed. It is an analogue of imipramine where one of the benzene rings has been replaced with a thiophene ring.

Mariptiline

Mariptiline (EN-207) is a tricyclic antidepressant (TCA) which was developed in the early 1980s, but was never marketed.

Homopipramol

Homopipramol is a tricyclic antidepressant and antipsychotic which was never marketed.

Mezepine

Mezepine is a tricyclic antidepressant (TCA) that was never marketed.

Naranol

Naranol (W-5494A) is a drug with a tricyclic-like structure. It was synthesized in the late 1960s, and was reported to have antidepressant, anxiolytic, and antipsychotic properties, but was never marketed.

Azipramine

Azipramine (TQ-86) is a tetracyclic antidepressant (TeCA) which was synthesized and assayed pharmacologically in animals in 1976, but was never marketed.

Enprazepine

Enprazepine is a tricyclic antidepressant (TCA) which was never marketed.

Ciclopramine

Ciclopramine is a tetracyclic antidepressant (TeCA) that was never marketed.

Amezepine

Amezepine is a tricyclic antidepressant (TCA) which was never marketed.

Amedalin

Amedalin (UK-3540-1) is an antidepressant which was synthesized in the early 1970s, but was never marketed. It is a selective norepinephrine reuptake inhibitor, with no significant effects on the reuptake of serotonin and dopamine, and no antihistamine or anticholinergic properties.

References

  1. ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN   0-412-54090-8.
  2. ↑ Triggle DJ (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN   0-412-46630-9.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.